A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
Abstract Immune response to biologics treatment, while widely reported, yet fails to correlate with clinical outcomes and assay to assay comparison is often not possible. Hence, we developed a new peptide based-detection assay to stratify pediatric patients with juvenile idiopathic arthritis (JIA) o...
Guardado en:
Autores principales: | Hendrik Rusche, Edoardo Marrani, Feliciana Real-Fernandez, Roberta Ponti, Francesco Terzani, Ilaria Maccora, Olivier Monasson, Maria Vincenza Mastrolia, Elisa Peroni, Ilaria Pagnini, Rolando Cimaz, Anna Maria Papini, Gabriele Simonini, Paolo Rovero |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cb1b521c419a45e9849274f9c708bf09 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
por: Kotaniemi K, et al.
Publicado: (2011) -
Adalimumab in patients with vision-threatening uveitis: real-world clinical experience
por: Peter J McCluskey, et al.
Publicado: (2021) -
Causes of uveitis in children without juvenile idiopathic arthritis
por: Engelhard SB, et al.
Publicado: (2015) -
Endothelin-1 Serum Concentration in Pediatric Chronic Idiopathic Uveitis
por: Powierza K, et al.
Publicado: (2021) -
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Linda Cingolani, et al.
Publicado: (2021)